Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, RVMD: OCF Margin % Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #798 out of 953 companies in the Biotechnology industry, placing it in the top 83.7%.
Is ADR Biomedical Holdings' OCF Margin % too high?
ADR Biomedical Holdings' current OCF Margin % is 0.00%. Based on the distribution chart, ADR Biomedical Holdings ranks #798 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #798 out of 953 companies for OCF Margin %. This places ADR Biomedical Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.72, compared to a current price of 円792.00 — trading 1894% above its estimated fair value. The current OCF Margin % is 0.00%. ADR Biomedical Holdings' overall GF Score™ is 31/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円792.00 is trading 1894% above its estimated GF Value™ of 円39.72.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
OCF Margin %: 0.00%
GF Value™: 円39.72 vs. price of 円792.00 (1894% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
31GF Score
Get the complete analysis for TSE:3750
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
